Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.

Yi-Wen HuangAlbert QinJane FangTing-Fang WangChung-Wei TsaiKo-Chung LinChing-Leou TengRichard Larouche

Published in: British journal of clinical pharmacology (2021)

Ropeginterferon alfa-2b up to 270 μg was safe and well tolerated. The PK/PD parameters of ropeginterferon alfa-2b showed increase in dose-response. Ropeginterferon alfa-2b had higher drug exposures and showed similar safety profile when compared to pegylated IFN alfa-2a at the same dose level.

Keyphrases

replacement therapy
clinical trial
immune response
dendritic cells
air pollution
open label